Citation for final published version:

Miner, Chundung Asabe, Timothy, Chikasirimobi G., Percy, Khathutshelo, Mashig, Mashige, Osuagwu, Uchechukwu Levi, Envuladu, Esther Awazzi, Amiebenomo, Onyekachukwu Mary-Anne, Ovenseri-Ogbomo, Godwin, Charwe, Deborah Donald, Goson, Piwuna Christopher, Ekpenyong, Bernadine N., Abu, Emmanuel Kwasi, Langsi, Raymond, Oloruntoba, Richard, Ishaya, Tanko and Agho, Kingsley E. 2023. Acceptance of COVID-19 vaccine among sub-Saharan Africans (SSA): a comparative study of residents and diasporan dwellers. BMC Public Health 23 , 191. 10.1186/s12889-023-15116-w file

Publishers page: https://doi.org/10.1186/s12889-023-15116-w

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Acceptance of COVID-19 vaccine among sub-Saharan Africans (SSA): a comparative study of residents and diasporan dwellers

Chundung Asabe Miner¹, Chikasirimobi G. Timothy², Khathutshelo Percy, Mashige³, Uchechukwu Levi Osuagwu¹,⁴,⁵, Esther Awazzi Enuladu⁶, Onyekachukwu Mary-Anne Amiebenomo⁷,⁸, Godwin Ovenseri-Ogbomo⁹,¹⁰, Deborah Donald Charwe¹⁰, Piwuna Christopher Goson¹¹, Bernadine N. Ekpenyong³,¹², Emmanuel Kwasi Abu¹³, Raymond Langsi¹⁴, Richard Oloruntoba¹⁵, Tanko Ishaya¹⁶ and Kingsley E. Agho³,⁵,¹⁷

Abstract

Background  The COVID-19 vaccines are being rolled out across all the sub-Saharan Africa (SSA) countries, with countries setting targets for achieving full vaccination rates. The aim of this study was to compare the uptake of, resistance and hesitancy to the COVID-19 vaccine between SSA locally residents and in the diasporan dwellers.

Methods  This was a cross-sectional study conducted using a web and paper-based questionnaire to obtain relevant information on COVID-19 vaccine acceptance. The survey items included questions on demography, uptake and planned acceptance or non-acceptance of the COVID-19 vaccines among SSAs. Multinomial logistic regression was used to determine probabilities of outcomes for factors associated with COVID-19 vaccination resistance and hesitancy among SSA respondents residing within and outside Africa.

Results  Uptake of COVID-19 vaccines varied among the local (14.2%) and diasporan (25.3%) dwellers. There were more locals (68.1%) who were resistant to COVID-19 vaccine. Participants' sex [adjusted relative risk (ARR) = 0.73, 95% CI: 0.58 – 0.93], education [primary/less: ARR = 0.22, CI:0.12 – 0.40, and bachelor’s degree: ARR = 0.58, CI: 0.43 – 0.77]), occupation [ARR = 0.32, CI: 0.25—0.40] and working status [ARR = 1.40, CI: 1.06—1.84] were associated with COVID-19 vaccine resistance among locals. Similar proportion of local and diasporan dwellers (~ 18% each) were hesitant to COVID-19 vaccine, and this was higher among health care workers [ARR = 0.25, CI: 0.10 – 0.62 and ARR = 0.24, CI:0.18—0.32, diaspora and locals respectively]. After adjusting for the potential confounders, local residents aged 29–38 years [ARR = 1.89, CI: 1.26—2.84] and lived in East Africa [ARR = 4.64, CI: 1.84—11.70] were more likely to report vaccine hesitancy. Knowledge of COVID vaccines was associated with hesitancy among local and diasporan dwellers, but perception was associated with vaccine resistance [ARR = 0.86, CI: 0.82 – 0.90] and hesitancy [ARR = 0.85, CI: 0.80 – 0.90], only among the local residents.

*Correspondence: Uchechukwu Levi Osuagwu l.osuagwu@westernsydney.edu.au
Full list of author information is available at the end of the article
Introduction
The coronavirus disease (COVID-19) pandemic that started in December of 2019, initially reported in Wuhan, China, has continued despite preventative measures adopted worldwide under the guidance of the World Health Organization (WHO). Many countries have experienced their second, third and fourth waves in terms of cases and resultant deaths [1–4]. The outbreak of the new Omicron variant in different countries [5–7] is of global concern [8], as it threatens the return to normalcy and the ongoing COVID-19 vaccination programmes. Non-pharmaceutical interventions to minimise the spread of infections included travel restrictions, lockdowns, physical distancing, regular handwashing and wearing of face masks [9, 10]. From the onset of the pandemic, scientists and pharmaceutical companies began the development of COVID-19 vaccines to offer protection against severe disease [11].

The Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson & Johnson, Sinopharm/BIBP and India’s Covishield [12, 13], vaccines are licensed for use across the globe. The utilisation of any vaccine can be influenced by system, client and provider factors [14], but in particular, vaccine acceptance plays a huge role for clients and providers. Generally, the acceptance of any vaccine has been shown to be influenced by demographic factors, knowledge of the disease and the consequences of contracting it, perceptions of susceptibility, potential benefits of a health action and the occurrence of one or more cues to action [11–17]. Similar factors may influence COVID-19 vaccine acceptance.

The COVID-19 vaccines have been shown to be efficient and safe [18], however, their acceptance is a major barrier to the successful rollout plans in different countries including the SSA region. This is further exacerbated by the mistrust in governments demonstrated by residents in this sub-region [19]. The WHO defines vaccine hesitancy as a ‘delay in acceptance or refusal of safe vaccines despite availability of vaccine services’ [20]. It is also stated to be one of the top ten threats to global health [21, 22]. Vaccine hesitancy is used to describe a phenomenon where individuals are unsure of getting vaccinated. Those who object to getting the vaccine are defined as vaccine resistant [23].

The success of vaccines depends on achieving maximum coverage and thereby attaining herd immunity [24]. Vaccine acceptance is therefore crucial to the efforts currently being made by public health experts of ensuring that the communities in every country are fully vaccinated. Studies have shown that there have been disparities in vaccine acceptance for other conditions, and factors such as age, race and ethnicity, social class, country and region of origin were associated with acceptance of vaccines [25, 26]. Similar results were reported for COVID-19 vaccines [27, 28].

Persons in the diaspora are “national migrant communities living in interaction among themselves and with their country of origin” [29]. Africans in the diaspora have been referred to by the African Union as “people of African origin living outside of the continent, irrespective of their citizenship and nationality, and who are willing to contribute to the development of the continent and the building of the African Union” [30]. It is generally believed that being in the diaspora provides Africans with greater opportunities to become more enlightened and therefore adopt different approaches to decision making [30]. Furthermore, studies have shown that there is geographical and spatial variation in the uptake of vaccines [31, 32]. In SSA, access to COVID-19 vaccines have improved, but the availability of vaccines and uptake remains substantially low compared with the rich European and North-American countries [33], and only 11% of the adult population in Africa were fully vaccinated as at January 2021 [34]. Although there are significant differences in the vaccination programmes and their rollout between countries [35, 36], the fact that a previous study found similarities in the attitude and risk perception towards COVID-19 among Africans living locally and those in the diaspora (mostly living in Western countries) during the lockdown, [37] suggests there could be similarities in their acceptance of the COVID-19 vaccination.

In low-middle income countries such as Nigeria which is in SSA, and others like India, Bangladesh (76.7%) and Egypt (42.6%), varying vaccine acceptance rates have been reported. Risks of COVID-19 infection and being male were factors that influenced COVID-19 vaccine acceptance (Patwary et al., 2022). Willingness to accept the COVID-19 vaccine was found to be high in Low-Middle income countries compared to USA and Russiaas

Conclusions
Differences exist in the factors that influence COVID-19 vaccine acceptance between local SSA residents and the diasporan dwellers. Knowledge about COVID-19 vaccines affects the uptake, resistance, and hesitancy to the COVID-19 vaccine. Information campaigns focusing on the efficacy and safety of vaccines could lead to improved acceptance of COVID-19 vaccines.

Keywords
Vaccination, Acceptance, COVID-19, Hesitancy, Resistance, Sub-Sahara Africa, Locals, Diaspora
reported by Solis Arce et al., 2022. Behaviour changes and outlooks in combination with perceived risks of COVID-19 disease informed the decision to accept the COVID-19 vaccine or not in most low-middle income countries of which most SSA countries are classified (Patwary et al., 2021). All those studies focused on the indigene and did not compare how the locals in a setting and indigenes living in locations outside their birth places perceive COVID-19 vaccination. This study, therefore, sought to investigate the differences in the acceptance of COVID-19 vaccination of sub-Saharan Africans living on the African continent and the diasporan dwellers. Although different studies exist that looked at COVID-19 vaccine acceptance, none had compared the same between SSAs who are resident locally and the diasporan dwellers at the time of this study.

Methods

Design and setting of the study
This was a web-based and paper-based cross-sectional survey carried out between 14th of March and 17th of May 2021. Due to the continued COVID-19 lockdowns in many of the target countries at the time of this study, web-based study was most appropriate even though it may have excluded some participants with no access to internet-based phone/computer services.

Characteristics of participants
The study population included adults who were 18 years and older, and living in sub-Saharan Africa countries (local residents) and those living in the diaspora (outside of Africa). Respondents from several countries in SSA, mostly from Cameroun, Ghana, Nigeria, South Africa, Tanzania, and those in diaspora mostly living in Australia, United Kingdom, United States, Saudi Arabia, Canada, China, and India took part in this study.

Sample size determination
The sample size was determined using Cochran’s formulae \( n = \frac{z^2pq}{d^2} \) with the assumption of a proportion of 50% at a confidence level of 95% with an error margin of 2.5%. A 20% non-response rate was assumed, and a minimum sample size of 2401 was obtained.

Survey instrument and data collection
Data was collected using a validated self-administered questionnaire adapted from a previous study [38]. The survey tool was tested for the internal validity of the items, and Cronbach’s alpha coefficient score ranged from 0.70 and 0.74, indicating satisfactory consistency [39]. The questionnaire was designed on survey monkey in both English and French, which are spoken languages in 26 and 21 SSA countries, respectively [40]. The questionnaire was disseminated electronically through an e-link on social media networks such as WhatsApp, Facebook and e-mail. There was an accompanying introductory section that included the background and goal of the study, procedure for participation and informed consent guide. Participants were requested on the introductory page not to participate in the survey more than once.

Confounding variables
The survey instrument showing the various variables collected has been presented as a supplementary material (Supplementary Table 1 [S1 Table]). The independent variables included sociodemographic variables; age, gender, region, marital status, the highest level of education, occupation, employment status, religion, smoking status, previous vaccination for other conditions and pre-existing medical conditions; knowledge of COVID-19 vaccines; perception of risk for contracting COVID-19; and attitude towards vaccination for COVID-19. Details of these variables were described in S1 Table. The exposure variable was the ‘place of residence’ (local or diasporea).

The COVID-19 vaccine knowledge items had 10 questions on a Likert scale with five levels as indicated in S1 Table 1. The scores for nine of the items ranged from 0 (lowest) to 4 (highest) while, for one item, it was coded as 1 for Yes and 0 for No. The overall knowledge towards COVID-19 vaccination score ranged from 0 -37 points, with a higher knowledge score indicating a better knowledge towards COVID-19 vaccination.

The attitude towards the COVID-19 vaccine items included four items with each assigned 2 points for ‘yes’, 1 point for ‘unsure’ and 0 point for ‘No’. The total attitude score ranged from 0 to 8, with a higher score denoting a better attitude towards COVID-19 vaccination.

The risk perception for contracting the disease after vaccination included questions on how the participants rate their risk of becoming infected with the virus and risk of dying from the infection. The responses were structured using a Likert scale with five levels (S1 Table), with scores for each item ranging from 0 (lowest) to 4 (highest). The total perception score ranged from 0 to 8, with a higher score representing a higher perception of contracting the infection following COVID-19 vaccination.

Main outcome variables
The main outcome variables were vaccine uptake, resistance and hesitancy. Uptake was determined by answering ‘yes’ to the question “Have you been vaccinated against COVID-19?”. The vaccine resistant group were those that answered ‘no’ to the question ‘Will you be willing to be
vaccinated against COVID-19 if the vaccine becomes available in your country?*, while those who answered ‘not sure’ were defined as the vaccine ‘hesitant’ group.

**Table 1** Characteristics (n = 2545) of the study participants living in (Local) and outside of Africa (Diaspora)

| Variables                        | Local 2391 (93.9%) | Diaspora 154 (6.1) | P-value <sup>^</sup> |
|----------------------------------|---------------------|--------------------|----------------------|
| **Age group (years)**            |                     |                    |                      |
| 18 – 28                          | 898 (38.7)          | 23 (14.9)          | <0.001               |
| 29 – 38                          | 677 (29.1)          | 41 (26.6)          |                      |
| 39 – 48                          | 450 (19.4)          | 46 (29.9)          |                      |
| 49+                              | 297 (12.8)          | 44 (28.6)          |                      |
| **Sex**                          |                     |                    |                      |
| Males                            | 1,264 (52.9)        | 112 (72.7)         | <0.001               |
| Females                          | 1,127 (47.1)        | 42 (27.7)          |                      |
| **SSA region of origin**<sup>^</sup> |              |                    |                      |
| West Africa                      | 1,330 (55.6)        | 107 (75.4)         | <0.001               |
| East Africa                      | 116 (4.9)           | 6 (4.2)            |                      |
| Central Africa                   | 288 (12.1)          | 24 (16.9)          |                      |
| Southern Africa                  | 657 (27.5)          | 5 (3.5)            |                      |
| **Marital status**               |                     |                    |                      |
| Married                          | 1,030 (43.1)        | 92 (59.7)          | <0.001               |
| Not married <sup>ǂ</sup>         | 1,361 (56.9)        | 62 (40.3)          |                      |
| **Highest level of education**   |                     |                    |                      |
| Postgraduate degree (Masters/PhD)| 668 (27.9)          | 82 (53.3)          | <0.001               |
| Bachelor’s degree                | 1,237 (51.7)        | 61 (39.6)          |                      |
| Secondary/High School            | 436 (18.2)          | 9 (5.8)            |                      |
| Primary or Less                  | 50 (2.1)            | 2 (1.3)            |                      |
| **Employment status**            |                     |                    |                      |
| Employed/Self-employed           | 1,733 (72.5)        | 139 (90.3)         | <0.001               |
| Unemployed/Retired               | 658 (27.5)          | 15 (9.7)           |                      |
| **Religion**                     |                     |                    |                      |
| Christianity                     | 2,140 (89.5)        | 138 (89.6)         | 0.966                |
| Others                           | 251 (10.5)          | 16 (10.4)          |                      |
| **Occupation**                   |                     |                    |                      |
| Non-Healthcare                   | 1,658 (69.3)        | 95 (61.7)          | 0.047                |
| Healthcare                       | 733 (30.7)          | 59 (38.3)          |                      |
| **Previous vaccination for any condition** | | | |
| No                               | 430 (18.0)          | 15 (9.7)           | 0.009                |
| Yes                              | 1,961 (82.0)        | 139 (90.3)         |                      |
| **Smoking Status**               |                     |                    |                      |
| Ex-smoker                        | 142 (5.9)           | 18 (11.7)          | 0.014                |
| Current smoker                   | 168 (7.0)           | 8 (5.2)            |                      |
| Non-smoker                       | 2,081 (87.0)        | 128 (83.1)         |                      |
| **Risk factors: Any pre-existing condition<sup>§</sup>** | | | |
| No                               | 2,022 (84.6)        | 107 (69.5)         | <0.001               |
| Yes                              | 369 (15.4)          | 47 (30.5)          |                      |

Data presented as frequencies (percentages)

<sup>^</sup> chi-square test were used to obtain the P—value

<sup>ǂ</sup> SSA Sub—Sahara Africa

<sup>ǂ</sup> includes single, divorced, and widowed

<sup>§</sup> includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney disease, any heart condition, sickle cell anemia

**Statistical analysis**

Data were analyzed using STATA/MP version 14 (Stata Corp 2015, College Station, TX, USA). A 95% confidence
interval (CI) was set for this survey, and a P-value of < 0.05 was considered statistically significant. Descriptive data were summarized and presented in tables and charts using frequencies, percentages, mean and standard deviations as required. Multinomial logistic regression analyses were used to examine the COVID-19 vaccination status on sources of information. As part of the multiple multinomial logistic regression analyses, a staged modelling technique was carried out. Elimination method was conducted using multiple multinomial logistic regression modelling techniques to remove statistically non-significant variables. Demographic factors were first entered into the baseline multiple regression model, followed by health indicator factors and the exposure variables were examined in the final model, which also included knowledge, attitude and risk perception variables, keeping only those variables significant in the previous model. In the final model, we tested and reported any co-linearity. The relative risk with 95% confidence intervals were calculated to assess the adjusted risks of independent variables.

Results
Characteristics of the respondents
There were a total of 2545 SSA respondents [2391 locals (93.9%) and 154 in the diaspora (6.1%)]. Table 1 shows the frequency and percentage distribution of respondents according to their socio-demographic variables. The majority of the SSA local residents (67.8%) were younger than 38 years, while those in the diaspora were older. There were more females than males in both groups, and the majority were originally from West Africa (locals 55.6%, diaspora 75.4%). More than half (56.9%) of the locals were not married, and 59.7% from the diaspora were married. Many locals had a bachelor’s degree (56.9%), and most diasporan participants were postgraduate degree holders (53.3%). Most respondents from both groups were employed /self-employed, predominantly non-healthcare workers and of the Christian faith. More than 80% of locals and above 90% of those in the diaspora had been previously vaccinated for one or two other conditions. More than two-thirds of the respondents indicated that they have never smoked. A higher proportion of respondents with preexisting conditions were locally resident (84.6%) compared to those in the diaspora (69.5%). Chi-square test results shown in Table 1 revealed statistically significant differences between the local and diasporan dwellers across all sociodemographic variables (P < 0.05, for all comparisons), with the exception of religion (P = 0.966).

Prevalence of uptake, resistance and hesitancy towards COVID-19 vaccine in SSA
Figure 1 presents the prevalence of vaccine uptake, resistance and hesitancy in both locals and those in the diaspora. The prevalence of COVID-19 vaccine uptake was almost twice higher among the diasporans (25.3%) than among the locals (14.2%). Resistance to the COVID-19 vaccine was more common among the locals (68.1%) than those in the diaspora (55.2%). Hesitancy to COVID-19 vaccine was almost the same for both locals and resident in the diaspora (See Fig. 1).

Distribution of vaccine uptake, resistance and hesitancy among local and diasporan residents
Table 2 shows the variations in the distribution of vaccine uptake, resistance and hesitancy across the demographic
variables as well as their mean scores for knowledge, attitude and perception of risk of infection. Those aged between 39 – 48 years had the highest proportion of locals that were resistant to the vaccine (70.0%) while among those in the diaspora, the 18 – 28 years’ age range had the highest proportion (73.9%). More males (70.2%) than females (65.7%) were resistant to taking the vaccine among the locals, whereas there was a preponderance of resistant females in the diasporan group (64.3%).

COVID-19 vaccine uptake was highest among Central African residents (20.1%) who lived locally but was highest among West Africans (29.9%) in the diaspora. The uptake of COVID-19 vaccine was highest among those with primary education or less (38.0%) while among those in the diaspora, uptake was highest among respondents with a master’s degree or higher (26.8%). Resistance was substantial in those with Master’s and higher degree respondents (70.7% for locals and 51.2% for those in the diaspora). For both healthcare and non-healthcare workers in both groups, the greatest proportions were resistant to taking the vaccine. The proportion of uptake, hesitancy and resistance towards COVID-19 vaccines varied with the employment status of the respondents, though the unemployed had the highest proportions of vaccine resistance in both groups (72.6% for locals and 60.0% for the diaspora). Christians represented the higher number of those who said they were hesitant to take the vaccine (18.6%) as compared with non-Christians in the diaspora (31.3%). Those who were ex-smokers had the highest proportion of those who were resistant among both the locals (69.0%) and those in the diaspora (72.2%). The uptake of the vaccine was also higher among those with pre-existing conditions in both local and diasporan respondents.

Higher mean scores for attitude and perception were observed among the COVID-19 vaccine uptake respondents for the local residents, while the mean knowledge score was highest for the hesitant group. Among the diasporans, the mean knowledge and perception scores were similarly highest in uptake respondents, but a higher score for attitude was observed in the hesitancy respondents (Table 2).

**Unadjusted analysis of factors associated with COVID-19 vaccine uptake, resistance and hesitancy in SSA**

Table 3 shows the unadjusted relative risk of factors associated with resistance and hesitancy towards COVID-19 vaccination among SSA respondents living locally and in the diaspora. Among the local residents, female sex was associated with the COVID-19 vaccine resistance [RR = 0.73, 95% CI: 0.58 – 0.93]. Local residency in East and Southern Africa was significantly associated with COVID-19 vaccine resistance [RR = 3.05, 95% CI: 1.31 – 7.08 and RR = 1.49, 95% CI: 1.12 – 2.00 respectively] and hesitancy [RR = 4.50, 95% CI: 1.83–11.02 and RR = 1.54, 95% CI: 1.09–2.19 respectively]. Having primary or less education was also associated with a lower risk of COVID-19 vaccine resistance [RR = 0.22, 95% CI: 0.12 – 0.41] and hesitancy [RR = 0.06, 95% CI: 0.01 – 0.25] among local residents.

Unemployment was significantly associated with higher risk of vaccine resistance [RR = 1.40, 95% CI: 1.06 – 1.84] among local residents. Being unmarried [RR = 0.74, 95% CI: 0.58 – 0.95], and having a history of vaccination for other conditions were associated with lower risk of vaccine resistance [RR = 0.39, 95% CI: 0.26 – 0.57] among locals. Also, those with high risk perception scores were significantly less likely to resist [RR = 0.88, 95% CI: 0.84 – 0.92] or be hesitant [RR = 0.90, 95% CI: 0.85–0.94] to the COVID-19 vaccines.

For those in diaspora, older age (> 38 years) [RR = 0.13, 95% CI: 0.03–0.65], working in healthcare sector [RR = 0.32, 95% CI: 0.25 – 0.40], having a more knowledge [0.82, 95% CI: 0.73–0.91] and better perception scores [RR = 0.77, 95% CI: 0.66 – 0.90], were associated with lower risk of COVID-19 vaccine resistance. Those who were not married were more likely to resist the COVID-19 vaccines compared with the married persons [RR = 2.34, 95% CI: 1.02–5.41].

**Adjusted analysis of factors associated with COVID-19 vaccine uptake, resistance and hesitancy in SSA**

Table 4 presents the associated factors of COVID-19 vaccine resistance and hesitancy in this study. After controlling for potential confounders in the local resident group, East African respondents were more likely to be resistant [ARR = 3.33, 95% CI: 1.40–7.94] and hesitant [ARR = 4.64, 95% CI: 1.84–11.70] towards receiving COVID-19 vaccines while Central African respondents were less likely to be resistant [ARR = 0.46, 95% CI: 0.32–0.68] or hesitant [ARR = 0.44, 95%CI: 0.27–0.72] towards the vaccines. Having a bachelor’s degree [ARR = 0.54, 95% CI: 0.38–0.76] or lower, being a health care worker [ARR = 0.24, 95% CI: 0.18–0.32], being previously vaccinated for any condition [ARR = 0.45, 95% CI: 0.30–0.69], and having a lower risk perception score [ARR = 0.86, 95% CI: 0.82 – 0.90] were associated with reduced risk of being resistant towards the COVID-19 vaccines among local residents in SSA. Among those in the diaspora, respondents who were aged 49 years and older [ARR = 0.17, 95% CI: 0.03 – 0.95], healthcare sector workers [ARR = 0.25, 95% CI: 0.10–0.62], as well as those with lower knowledge scores [ARR = 0.82, 95% CI: 0.73 – 0.91] were less likely to resist taking the COVID-19 vaccines.
Table 2  Prevalence of vaccine uptake, hesitancy and resistance among SSAs living in (local) and outside Africa (diaspora)

| Variable                                 | LOCAL Uptake n = 340 | Resistant n = 1627 | Hesitant n = 424 | DIASPORA Uptake n = 39 | Resistant n = 85 | Hesitant n = 30 |
|------------------------------------------|----------------------|--------------------|------------------|------------------------|-----------------|----------------|
| Age in years                              |                      |                    |                  |                        |                 |                |
| 18 – 28                                   | 127 (14.1)           | 621 (69.2)         | 150 (16.7)       | 2 (8.7)                | 17 (73.9)       | 4 (17.0)       |
| 29 – 38                                   | 101 (14.9)           | 435 (64.3)         | 141 (20.8)       | 3 (7.3)                | 25 (61.0)       | 13 (31.0)      |
| 39 – 48                                   | 61 (13.6)            | 315 (70.0)         | 74 (16.4)        | 18 (39.1)              | 20 (43.5)       | 8 (17.0)       |
| 49 +                                     | 33 (11.1)            | 205 (69.0)         | 59 (19.9)        | 16 (36.4)              | 23 (52.3)       | 5 (11.0)       |
| Sex                                       |                      |                    |                  |                        |                 |                |
| Males                                     | 159 (12.6)           | 887 (70.2)         | 218 (17.3)       | 32 (28.6)              | 58 (51.8)       | 22 (19.6)      |
| females                                   | 181 (16.1)           | 740 (65.7)         | 206 (18.3)       | 7 (16.7)               | 27 (64.3)       | 8 (19.1)       |
| Region                                    |                      |                    |                  |                        |                 |                |
| West Africa                               | 205 (15.4)           | 897 (67.4)         | 228 (17.1)       | 32 (29.9)              | 54 (50.5)       | 21 (19.6)      |
| East Africa                               | 6 (5.2)              | 80 (69.0)          | 30 (25.9)        | 0 (0.0)                | 3 (50.0)        | 3 (50.0)       |
| Central Africa                            | 58 (20.1)            | 186 (64.6)         | 44 (15.3)        | 6 (25.0)               | 16 (66.7)       | 2 (8.3)        |
| Southern Africa                           | 71 (10.8)            | 464 (70.6)         | 122 (18.6)       | 0 (0.0)                | 4 (80.0)        | 1 (20.0)       |
| Level of education                        |                      |                    |                  |                        |                 |                |
| Master’s degree and higher                | 68 (10.2)            | 472 (70.7)         | 128 (19.2)       | 22 (26.8)              | 42 (51.2)       | 18 (22.0)      |
| Bachelor’s degree                         | 204 (16.5)           | 815 (65.9)         | 218 (17.6)       | 14 (23.0)              | 38 (62.3)       | 9 (14.8)       |
| Secondary/high school                     | 49 (11.2)            | 311 (71.3)         | 76 (17.4)        | 3 (33.3)               | 4 (44.4)        | 2 (22.2)       |
| Primary/no school                         | 19 (38.0)            | 29 (58.0)          | 2 (4.0)          | 0 (0.0)                | 1 (50.0)        | 1 (50.0)       |
| Occupation                                |                      |                    |                  |                        |                 |                |
| Non-healthcare                            | 157 (9.0)            | 1,188 (71.2)       | 313 (18.9)       | 17 (17.9)              | 61 (64.2)       | 17 (17.9)      |
| Healthcare                                | 183 (25.0)           | 439 (59.9)         | 111 (15.1)       | 22 (37.3)              | 24 (40.7)       | 13 (19.5)      |
| Working status                            |                      |                    |                  |                        |                 |                |
| Employed                                  | 262 (15.1)           | 1,149 (66.3)       | 322 (18.5)       | 38 (27.3)              | 76 (54.7)       | 25 (18.0)      |
| Unemployed                                | 78 (11.9)            | 478 (72.6)         | 102 (15.5)       | 1 (6.7)                | 9 (60.0)        | 5 (33.3)       |
| Marital/family status                     |                      |                    |                  |                        |                 |                |
| Married                                   | 126 (12.2)           | 719 (69.8)         | 185 (18.0)       | 29 (31.5)              | 47 (51.1)       | 16 (17.4)      |
| Not married †                             | 214 (15.7)           | 908 (66.7)         | 239 (17.6)       | 10 (16.1)              | 38 (61.3)       | 14 (22.6)      |
| Religion                                  |                      |                    |                  |                        |                 |                |
| Christians                                | 304 (14.2)           | 1,439 (67.2)       | 397 (18.6)       | 35 (25.4)              | 78 (56.5)       | 25 (18.1)      |
| Others                                    | 36 (14.3)            | 188 (74.9)         | 27 (10.8)        | 4 (25.0)               | 7 (43.8)        | 5 (31.3)       |
| Smoking status                            |                      |                    |                  |                        |                 |                |
| Ex-smoker                                 | 21 (14.8)            | 98 (69.0)          | 23 (16.2)        | 4 (22.2)               | 13 (72.2)       | 1 (5.6)        |
| Current smoker                            | 20 (11.9)            | 113 (67.3)         | 35 (20.8)        | 1 (12.5)               | 5 (62.5)        | 2 (25.0)       |
| Non-smoker                                | 299 (14.4)           | 1,627 (68.1)       | 424 (17.7)       | 34 (26.6)              | 67 (52.3)       | 27 (21.1)      |
| Have you been vaccinated for any condition|                      |                    |                  |                        |                 |                |
| No                                        | 30 (7.0)             | 326 (75.8)         | 74 (17.2)        | 3 (20.0)               | 9 (60.0)        | 3 (20.0)       |
| Yes                                       | 310 (14.2)           | 1,301 (66.3)       | 350 (17.9)       | 36 (25.9)              | 76 (54.7)       | 27 (19.4)      |
| Any pre-existing conditions §             |                      |                    |                  |                        |                 |                |
| No                                        | 280 (13.9)           | 1,383 (68.4)       | 359 (17.6)       | 23 (21.5)              | 61 (57.0)       | 23 (21.5)      |
| Yes                                       | 60 (16.3)            | 244 (66.1)         | 65 (17.6)        | 16 (34.0)              | 24 (51.1)       | 7 (14.9)       |
| Knowledge *                               | 18.7 ± 4.9           | 18.5 ± 6.3         | 19.6 ± 3.6       | 22.7 ± 3.4             | 18.9 ± 0.6      | 20.5 ± 3.8     |
| Attitude *                                | 1.2 ± 2.2            | 0.9 ± 2.1          | 1.0 ± 2.0        | 0.7 ± 1.9              | 0.7 ± 1.8       | 1.3 ± 2.2      |
| Perception *                              | 6.7 ± 2.7            | 5.6 ± 3.1          | 5.8 ± 2.3        | 7.2 ± 2.4              | 5.3 ± 3.1       | 5.9 ± 2.9      |

*Data presented as mean ± standard deviation
† includes single, divorced and widowed.
§ includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney disease, any heart condition, sickle cell anemia
Table 3  Relative risk (RR) for factors associated with COVID-19 vaccine uptake, hesitancy and resistance among SSA locals and diasporans. The base reference was COVID-19 vaccine uptake for all variables

| Variable                          | LOCAL                              |                         | DIASPORA                           |                         |
|-----------------------------------|------------------------------------|-------------------------|------------------------------------|-------------------------|
|                                   | Resistant RR (95%CI)               | Hesitant RR (95%CI)     | Resistant RR (95%CI)               | Hesitant RR (95%CI)     |
| Age in years                      |                                    |                         |                                    |                         |
| 18 – 28                           | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| 29 – 38                           | 0.88 (0.66—1.18)                   | 1.18 (0.83—1.67)       | 0.98 (0.15—6.50)                   | 2.17 (0.26—17.89)       |
| 39 – 48                           | 1.06 (0.76—1.47)                   | 1.03 (0.68—1.55)       | 0.13 (0.03—0.65)                   | 0.22 (0.03—1.47)        |
| 49+                               | 1.27 (0.84—1.92)                   | 1.51 (0.93—2.46)       | 0.17 (0.03—0.84)                   | 0.16 (0.02—1.12)        |
| Sex                               |                                    |                         |                                    |                         |
| Males                             | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Females                           | 0.73 (0.58—0.93)                   | 0.83 (0.62—1.10)       | 2.13 (0.83—5.43)                   | 1.66 (0.53—5.25)        |
| Region                            |                                    |                         |                                    |                         |
| West Africa                       | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| East Africa                       | 3.05 (1.31—7.08)                   | 4.50 (1.83—11.02)      | -                                  | -                      |
| Central Africa                    | 0.73 (0.53—1.02)                   | 0.68 (0.44—1.05)       | 1.58 (0.56—4.45)                   | 0.51 (0.09—2.76)        |
| Southern Africa                   | 1.49 (1.12—2.00)                   | 1.54 (1.09—2.19)       | -                                  | -                      |
| Level of education                |                                    |                         |                                    |                         |
| Master's degree and more          | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Bachelor's degree                 | 0.58 (0.43—0.77)                   | 0.57 (0.40—0.81)       | 1.42 (0.64—3.17)                   | 0.79 (0.28—2.23)        |
| Secondary/High School             | 0.91 (0.62—1.36)                   | 0.82 (0.52—1.31)       | 0.70 (0.14—3.40)                   | 0.81 (0.12—5.42)        |
| Primary/Less                      | 0.22 (0.12—0.41)                   | 0.06 (0.01—0.25)       | -                                  | -                      |
| Occupation                        |                                    |                         |                                    |                         |
| Non-healthcare                    | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Healthcare                        | 0.32 (0.25—0.40)                   | 0.30 (0.22—0.41)       | 0.30 (0.14—0.67)                   | 0.59 (0.23—1.54)        |
| Working status                    |                                    |                         |                                    |                         |
| Employed                          | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Unemployed                        | 1.40 (1.06—1.84)                   | 1.06 (0.76—1.49)       | 4.0 (0.55—36.83)                   | 7.60 (0.84—68.97)       |
| Marital/family status             |                                    |                         |                                    |                         |
| Married                           | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Not married ‡                     | 0.74 (0.58—0.95)                   | 0.76 (0.57—1.02)       | 2.34 (1.02—5.41)                   | 2.54 (0.92—7.00)        |
| Religion                          |                                    |                         |                                    |                         |
| Christians                        | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Others                            | 1.10 (0.76—1.61)                   | 0.57 (0.34—0.97)       | 0.79 (0.22—2.86)                   | 1.75 (0.43—7.18)        |
| Smoking status                    |                                    |                         |                                    |                         |
| Ex-smoker                         | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Current smoker                    | 1.21 (0.62—2.36)                   | 1.60 (0.71—3.58)       | 1.54 (0.14—17.33)                  | 8.0 (0.31—206.37)       |
| Non-smoker                        | 1.01 (0.62—1.65)                   | 1.12 (0.61—2.06)       | 0.61 (0.18—2.00)                   | 3.18 (0.34—30.10)       |
| Have you been vaccinated for any condition |                                    |                         |                                    |                         |
| No                                | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Yes                               | 0.39 (0.26—0.57)                   | 0.46 (0.29—0.72)       | 0.70 (0.18—2.76)                   | 0.75 (0.14—4.01)        |
| Any pre-existing conditions ⁶     |                                    |                         |                                    |                         |
| No                                | 1.00                               | 1.00                    | 1.00                               | 1.00                    |
| Yes                               | 0.82 (0.60—1.12)                   | 0.84 (0.58—1.24)       | 0.57 (0.26—1.25)                   | 0.44 (0.15—1.26)        |
| Knowledge                         | 0.99 (0.97—1.01)                   | 1.03 (1.01—1.06)       | 0.82 (0.73—0.91)                   | 0.87 (0.77—0.98)        |
| Attitude                          | 0.96 (0.91—1.01)                   | 0.96 (0.90—1.03)       | 0.99 (0.80—1.24)                   | 1.15 (0.90—1.46)        |
| Perception                        | 0.88 (0.84—0.92)                   | 0.90 (0.85—0.94)       | 0.77 (0.66—0.90)                   | 0.84 (0.70—1.01)        |

If 95% confidence intervals (CI) around RRs that lies between 1.00 indicate not statistically significant. All comparisons were made against vaccinated pregnant women (RR=1.0).

‡ includes single, divorced, and widowed

⁶ includes the presence of any of the following conditions: cancer, diabetes, hypertension, asthma, kidney disease, any heart condition, sickle cell anemia
Regarding COVID-19 vaccine hesitancy among local residents in SSA, the significant factors included East and Central African origin, aged between 29 – 38 years, being a health care worker, having a bachelor’s degree or less, non-Christians, having been previously vaccinated for other conditions, higher knowledge and lower perception scores. For those in the diaspora, being a health care worker \( [ARR = 0.46, 95\% CI: 0.16 – 1.35] \) and having lower knowledge scores \( [ARR = 0.88, 95\% CI: 0.77 – 0.99] \) were the factors that were significant for being hesitant.

### Discussion

The purpose of this study was to compare the uptake, resistance and hesitancy of the COVID-19 vaccine between locally resident SSAs and those in the diaspora. Uptake of the COVID-19 vaccine was found to be twice as high among residents in the diaspora compared to local SSA residents. The WHO and Centers for Disease Control and Prevention (CDC) have suggested that the low vaccination rates in low-and-middle-income countries is in part, due to inequitable distribution of vaccines. Accessibility to vaccines may have played a role in the low uptake rates in our study. Half of the 52 African countries that had received vaccines had only vaccinated up to 2% of their population at the time of this study, and 15 countries had vaccinated up to 10% \[41\]. However, majority of those residing in Africa and the diaspora were either resistant or hesitant to get vaccinated. This finding is different from that reported in a previous study \[42\] where a higher proportion of African residents and those in the diaspora were willing to accept the vaccine when offered. A survey conducted by CDC Africa prior to the introduction of vaccines on the continent found that the willingness to take the vaccine in 15 African countries ranged from 59 to 93% \[43\], which was in contrast with our findings of greater resistance towards COVID-19 vaccination. Studies conducted in the US and UK showed that Africans/Blacks were 13 times more likely to be hesitant than Whites \[44, 45\] which is similar to the high proportions of SSA in diaspora who were either hesitant or resistant to taking COVID-19 vaccines.

Socio-demographic characteristics have been shown to play significant roles in vaccine hesitancy and resistance \[45\]. In this study, age, region of origin, educational level, occupation and religion were significantly associated with either vaccine hesitancy or resistance among local and diasporan residents. Younger age groups among the local residents were almost twice

### Table 4

| Variable                  | Local |             |             | Diaspora |             |             |
|---------------------------|-------|-------------|-------------|----------|-------------|-------------|
|                           | Resistant | Resistant | Hesitant | Hesitant | Resistant | Resistant |
|                           | ARR (95%CI) | ARR (95%CI) | ARR (95%CI) | ARR (95%CI) | ARR (95%CI) | ARR (95%CI) |
| 18 – 28 years              | 1.00   | 1.00        | 1.00       | 1.00     |
| 29 – 38 years              | 1.32 (0.94—1.85) | 1.89 (1.26—2.84) | 1.35 (0.18 – 10.07) | 2.6 (0.30 – 23.17) |
| 39 – 48 years              | 1.28 (0.867—1.89) | 1.29 (0.80—2.07) | 0.21 (0.04 – 1.17) | 0.29 (0.04—2.08) |
| 49+ years                  | 1.39 (0.86—2.23) | 1.74 (1.00—3.05) | 0.17 (0.03 – 0.95) | 0.15 (0.02 – 1.16) |
| West Africa                | 1.00   | 1.00        | -          | -        |
| East Africa                | 3.33 (1.40—7.94) | 4.64 (1.84—11.70) | -          | -        |
| Central Africa             | 0.46 (0.32—0.68) | 0.44 (0.27—0.72) | -          | -        |
| Southern Africa            | 1.32 (0.94—1.84) | 1.39 (0.94—2.06) | -          | -        |
| Master’s & above           | 1.00   | 1.00        | -          | -        |
| Bachelor’s degree          | 0.54 (0.38—0.76) | 0.60 (0.40—0.90) | -          | -        |
| Secondary/ high School     | 0.52 (0.31—0.87) | 0.56 (0.31—1.02) | -          | -        |
| Primary & Less             | 0.15 (0.07—0.32) | 0.05 (0.01—0.24) | -          | -        |
| Non-health care            | 1.00   | 1.00        | 1.00       | 1.00     |
| Health care                | 0.24 (0.18—0.32) | 0.19 (0.13—0.27) | 0.25 (0.10—0.62) | 0.46 (0.16—1.35) |
| Christians                 | 1.00   | 1.00        | -          | -        |
| Others                     | 0.96 (0.64—1.46) | 0.50 (0.29—0.86) | -          | -        |
| Vaccinated for any condition | 0.45 (0.30—0.69) | 0.48 (0.29—0.77) | -          | -        |
| Knowledge                  | 1.02 (1.00 – 1.05) | 1.07 (1.04 – 1.11) | 0.82 (0.73 – 0.91) | 0.88 (0.77 – 0.99) |
| Perception                 | 0.86 (0.82 – 0.90) | 0.85 (0.80 – 0.90) | -          | -        |

If 95% confidence intervals (CI) around RRs that lies between 1.00 indicate not statistically significant. All comparisons were made against vaccinated pregnant women \( [RR = 1.0] \)
likely to be hesitant and older age groups were less likely to be resistant to vaccines. This finding is consistent with other previous studies [32, 37, 45, 46], and may also be related to the fact that COVID-19 is more likely to present in the severe form among older age groups, making them more likely to accept the vaccine for their protection.

Local East African respondents were three times more likely to resist and almost five times more likely to be hesitant than West Africans. This may be due to misinformation about COVID-19 [47] and its vaccines [48] which was reported to be more common in East African countries such as Tanzania. The results showed that the least educated respondents were less likely to be resistant or hesitant. This may be as a result of not comprehending the scientific arguments being advanced against the vaccines and having to make choices based on past experiences or the information they do understand. A recent study in the US showed a similar pattern with those with lower levels of education showing less hesitancy than those with higher [48]. This is contrary to the results obtained in other studies [35–37, 41, 42]. A statement by a 61 year old on Africa news may provide an insight into the mindset of those who are less educated thereby making them more likely to accept vaccination: "If in the time of our mothers, in the time we were little children if these "WhatsApp doctors" had existed (people who post unreliable medical information on social media) I think we would have all died because our mothers who did not go to school agreed to vaccinate us against smallpox, measles, polio – all the other diseases without debate. Today, we are more educated, but curiously, we refuse vaccination. This is a certain danger for our society, according to what I have read here and there. The Congo is being blacklisted because we risk many deaths if we don’t accept vaccination" [49].

Both local and diasporan healthcare workers showed less likelihood of being either resistant or hesitant as compared to non-healthcare workers in this study. Resistance and hesitancy have been found among health workers though lower when compared to non-healthcare workers [50–55]. However, Blacks /African health workers still show higher risk than their counterparts of being resistant/hesitant irrespective of the country they are in. Vaccine resistance and/or hesitancy is a hindrance to the vaccination campaign, as such, health workers who should be well educated about the vaccines are likely to exert an influence on others and possibly deter them from getting vaccinated. Most findings in the cited papers found that the fear of side effects was usually the reason for hesitancy and resistance among health workers. [51–53]

Among the local residents, individuals from other religions were less likely to be vaccine hesitant compared to those of the Christian faith. Religion has been reported to play a huge role in the life of Africans and influences their health seeking behavior [56, 57]. Olagoke et al. reported that some religious views have contributed to the rejection of vaccination [58]. However, an intervention study conducted among American Christians [59], showed that with proper presentation of scientific facts, such negative views can be changed. Community engagement with religious leaders has also been advocated as a means of addressing vaccine hesitancy [60].

Local residents who had been previously vaccinated for other conditions were less likely to be COVID-19 vaccine resistant or hesitant. This finding emphasizes the influence of past experiences which can build confidence in the efficacy of vaccines. Other studies have also shown a willingness to be vaccinated among those who had previously received vaccinations for other diseases such as flu, yellow fever, hepatitis [61, 62]. Knowledge of COVID-19 vaccine was a significant factor among both local and diasporan residents. Knowledge has been shown to reduce resistance to vaccine acceptance. Africans in the diaspora were less likely to be hesitant or resistant to vaccines as compared to their counterparts residing in Africa. This may still be related to misinformation and the need for health messages to be relayed in the languages familiar to the people. Recent studies have shown a decline in those who are hesitant and this has been attributed to the availability of accurate information that reduces fear and leads to making informed decisions [63]. Exposure to accurate information and increased knowledge about COVID-19 vaccines may help those who are hesitant to be more receptive to vaccines. Among local residents, higher perception scores showed a lower odd of being either resistant or hesitant. The perception that one is likely to be at risk of contracting a disease can result in people taking appropriate measures to protect themselves from contracting the disease.

**Strengths and limitations**

This is the first large scale study to compare acceptance of COVID-19 vaccines between sub-Saharan African local residents and those in the diaspora. The study employed robust analyses to control for potential confounders to reduce the possibility of a bias. The distribution of the questionnaire in both English and French languages was through an internet-based methodology, which was the only reliable means to disseminate information at the time of this study to a wider audience. Notwithstanding these strengths, the study has some limitations. For example, the study did not explore concerns about vaccine safety
which may be an important determinant of vaccine hesitancy. The cross-sectional nature of the study means that causation cannot be determined. The survey was distributed electronically using social media platforms and emails, and this may have inadvertently excluded some potential participants whose opinions may have differed, such as those without internet access and people living in rural areas, where internet penetration remains relatively low [64]. The survey was presented in English and French and thus inadvertently excluding some of the Portuguese or Arabic-speaking SSA countries from participating. Although the study showed satisfactory internal validity, its generalization or transferability to all SSA countries may be limited. Despite the wide distribution of the survey, only few SSA living in diaspora participated compared to many who lived in SSA. However, robust analysis was conducted through the use of proportions for comparison and the use of regression analysis to ensure adequate control of potential confounders.

Conclusions
The study showed that Africans residing both locally and in diaspora are mostly either resistant or hesitant to the COVID-19 vaccines. Factors that influenced resistance and hesitancy among local residents included younger age, East and Central African residency, lower levels of education, history of previous vaccinations, being a healthcare sector worker, knowledge and perceptions of COVID-19 vaccine. For Africans in the diaspora, being hesitant or resistant to COVID-19 vaccines are influenced by older age, being a healthcare sector worker and having adequate knowledge of vaccines. The implication of these findings is that continued hesitancy and resistance to the COVID-19 vaccines by Africans irrespective of where they are based could jeopardise the progress made by countries in the distribution of the vaccines and subsequent control of the spread of the virus. Future research could explore if the factors identified in this study are also playing a role in hesitancy/resistance to other vaccines. Appropriate interventions such as public health messaging that take into consideration the different influencing factors are required to enhance COVID vaccine uptake to achieve sufficient vaccine coverage.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12889-023-15116-w.

Additional file 1:

Acknowledgements
Research reported in this publication was partially supported by the South African Medical Research Council under a Self-Initiated Research Grant.

Authors’ contributions
U.L.O, K.A and K.P.M. conceptualized the study. C.A.M., C.G.T., K.P.M., U.L.O., G.O, D.D.C, P.C.G, B.N.E, E.K.A, R.L., R.O, T.I., K.O. and K.R. were involved in the study design and data collection. K.A and U.L.O performed the formal analysis of the data. C.A.M., C.G.T, drafted the original manuscript. K.P.M., U.L.O., E.A. E., O.M.A, G.O, D.D.C, P.C.G, B.N.E, E.K.A, R.L., R.O, T.I., and K.R. reviewed and edited the manuscript. K.A, U.L.O., K.P.M., and T.I. supervised the project. All author(s) read and approved the final manuscript.

Funding
No external funding was obtained for this study.

Availability of data and materials
The datasets used and/or analysed in this study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Ethical approval to conduct the study was obtained from the Humanities and Social Sciences Research Ethics Committee (approval #: HSSREC 00002504/2021) of the University of KwaZulu-Natal, Durban, South Africa. The study adhered to the tenets of the Declaration of Helsinki involving human participants [65], and anonymous voluntary informed consent was obtained from all participants as part of the preamble accompanying the questionnaire. Participants were included in this study if they were of African origin, aged 18 years and older, and provided consent. Completion of the questionnaire was only possible after the participants had responded to the consent question: ‘do you voluntarily take part in this study?’ Those who answered ‘No’ to this question were automatically locked out from the survey platform.

Consent for publication
Not applicable.

Competing interests
The authors declare that we have no competing interest.

Author details
1Department of Community Medicine, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria. 2Department of Optometry, Mzuzu University, Mzuzu, Malawi. 3African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 4Bathurst Rural Clinical School, School of Medicine, Western Sydney University, Bathurst, NSW 2795, Australia. 5Translational Health Research Institute (THRI), Western Sydney University, 2506 New South Wales, Australia. 6Department of Community Medicine, College of Health Sciences, University of Jos, Jos, Nigeria. 7School of Optometry and Vision Sciences, College of Biomedical Sciences, Cardiff University, Cardiff, UK. 8Department of Optometry, Faculty of Life Sciences, University of Benin, Benin City, Ugbowo, Nigeria. 9Department of Optometry, Centre for Health Sciences, University of the Highlands and Islands, Inverness, UK. 10Tanzania Food and Nutrition Center, Dar-Es-Salaam, Tanzania. 11Department of Psychiatry, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria. 12Department of Public Health, Faculty of Allied Medical Sciences, College of Medical Sciences, University of Calabar, Cross River State, Calabar, Nigeria. 13Department of Optometry and Vision Science, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana. 14Health Division, University of Bamenda, Bambili, Cameroon. 15School of Management and Marketing, Curtin University, Kent
References

1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020(43)(4):328–33.

2. Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ, et al. Comparison of the second and third waves of the COVID-19 pandemic in South Korea: importance of early public health intervention. Int J Infect Dis. 2021;104:742–5.

3. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet. 2021;397(10281):1265–75.

4. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA. 2022;327(6):583–4. https://doi.org/10.1001/jama.2022.24688. PubMed PMID: 34967859; PubMed Central PMCID: PMC8719272.

5. Grabowski E, Koczarczyk M, Lipiński T. The spread of SARS-Cov-2 Omicron variant with a doubling time of 2.0–3.3 days can be explained by immune evasion. Viruses. 2022;14(2):294.

6. Brandal LT., MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021; 26(50). pii:eur211147. https://doi.org/10.2807/1560-7917.ES.2021.26.50.2101147.

7. Helmsdal G, Hansen OK, Møller LF, Christiansen DH, Petersen MS, Krichtsien MF. Omicron outbreak at a private gathering in the Faroe Islands, infecting 21 of 33 triple-vaccinated healthcare workers. Clin Infect Dis. 2022;75(5):893–6. https://doi.org/10.1093/cid/ciaa417. Epub 2022 Jan 11. PubMed PMID: 34902535.

8. Saxena SK, Kumar S, Ansari S, Paveska JT, Maurya VK, Tripathi AK, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94(4):1738–44. https://doi.org/10.1002/jmv.27524. Epub 2022 Jan 26. PubMed PMID: 34971272.

9. Odusanya OO, Odugbemi BA, Odugbemi TO, Ajisegiri WS. COVID-19: a review of the effectiveness of non-pharmacological interventions. Niger J Clin Pract. 2022;34(9):34905235.

10. Gokmen Y, Baskici C, Ercil Y. Effects of non-pharmaceutical interventions. Niger J Clin Pract. 2022;34(9):34905235.

11. Schuchat A. Human vaccines and their importance to public health. Postgrad Med J. 2020;27(4):261–7. https://doi.org/10.1136/postgradmedj.2022.00372.

12. World Health Organization [Internet]. Draft landscape and tracker of COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Lancet Microbe. 2021;2(7):e279–80.

13. Kamal AHM, Sarkar T, Khan MM, Roy SK, Khan SH, Hasam SMM, et al. Factors affecting willingness to receive COVID-19 vaccine among adults: a cross-sectional study in Bangladesh. J Health Manag. 2021. https://doi.org/10.1177/0973984221105069.

14. Olliaro P, Torrelee E, Vallant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Lancet Microbe. 2021;2(7):e279–80.

15. Cho W, Kwon SF, Huh JM, Kim SW, Kim YS, Kim JW, et al. Individual factors influencing COVID-19 vaccine acceptance in Korea: importance of early public health intervention. Int J Infect Dis. 2021;94:1738–44. https://doi.org/10.1016/j.ijid.2020.11.064. PubMed PMID: 34966172; PubMed Central PMCID: PMC8537475.

16. Razai MS, Chaudhry U A R, Doehnelt K, Baudl L, Majeed A. Covid-19 vac‑cine hesitancy. BMJ. 2021;373:n138.

17. World Health Organization [Internet]. Ten threats to global health in 2019; c2019 [cited 2022 Jan 23]. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.

18. Geoghegan S, O’Callaghan KP, Offit PA. Vaccine safety: myths and misinformation. Front Microbiol. 2020;11(1):372. https://doi.org/10.3389/fmicb.2020.00372.

19. Umanakanth S, Patil S, Subramaniam N, Sharma R. COVID-19 vaccine hesitancy and resistance in India explored through a population-based longitudinal survey. Vaccines (Basel). 2021;9(10):1064. https://doi.org/10.3390/vaccines9101064. PubMed PMID: 3469172; PubMed Central PMCID: PMC8537475.

20. Kini A, Morgan R, Kuo H, Shea P, Shapiro J, Lieng SX, et al. Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race. Vaccine. 2022;40(11):1643–54.

21. Niederhauser VP, Stark M. Narrowing the gap in childhood immunization disparities. Pediatr Nurs. 2005;31(5):380–6. PubMed PMID: 16295153.

22. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No populations left behind: vaccine hesitancy and equitable diffusion of effective COVID-19 vaccines. J Gen Intern Med. 2021;36(7):2130–3.

23. Malik AA, McFadden SM, Elharaie J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. ECLinicalMedicine. 2020;26:100495. Epub 2020 Aug 12.

24. The ICD “Experience Africa” Program [Internet]. The African Diaspora. Introduction to the African Diaspora across the World; c2021 [cited 2022 Jan 23]. Available from: https://www.experience-africa.org/index.php/en-the-african-diaspora.

25. African Diaspora [Internet]. Meeting of Experts on the Definition of the African Diaspora 11 – 12 April 2005 Addis Ababa, Ethiopia. Report of the meeting of experts from members of States on the definition of African Diaspora; c2021 [cited 2022 Jan 23]. Available from: http://www.dirco.gov.za/diaspora/definition.html.

26. Riesen M, Konstantinoudis G, Lang P, Low N, Hatz C, Maeusezahl M, et al. Exploring variation in human papillomavirus vaccination uptake in Switzerland: a multilevel spatial analysis of a national vaccination coverage survey. BMJ Open. 2018;8(5):e021006 PubMed PMID: 29737702; PubMed Central PMCID: PMC5961588.

27. McAuslane H, Utsi L, Wensley A, Coole L. Inequalities in maternal pertussis vaccine uptake: a cross-sectional survey of maternity units. J Public Health. 2018;40(1):121–8. https://doi.org/10.1093/pubmed/fdx032.

28. Basak P, Abr T, Al Mamun A, Zainor NL, Khaman MR, Haque MR, et al. A global study on the correlates of Gross Domestic Product (GDP) and COVID-19 vaccine distribution. Vaccines. 2022;10(2):266. https://doi.org/10.3390/vaccines1002066.

29. World Health Organization [Internet]. Africa on track to control COVID-19 pandemic in 2022; c2022 [cited 2022 Jan 23]. Available from: https://www.afro.who.int/news/africa-track-control-covid-19-pandemic-2022.

30. World Health Organization Regional Office for Africa [Internet]. Risks and challenges in Africa’s COVID-19 vaccine rollout; c2022 [cited 2022 Jan 23]. Available from: https://www.afro.who.int/news/risks-and-challenges-afric‑as‑covid‑19‑vaccine‑rollout.

31. Dzinamarira T, Nachipo B, Phiri B, Musuka G. COVID-19 vaccine roll-out in South Africa and Zimbabwe: urgent need to address uncertainty preparedness, fears and hesitancy. Vaccines. 2021(9)(3):250. https://doi.org/10.3390/vaccines9030250.
37. Abu EK, Oloruntoba R, Osuagwu UL, Bhattachar D, Miner CA, Goson PC, et al. Risk perception of COVID-19 among sub-Saharan Africans: a web-based comparative survey of local and diaspora residents. BMC Public Health. 2021;21(1):1562. https://doi.org/10.1186/s12889-021-11600-3.

38. Geldsetzer P. Use of rapid online surveys to assess people’s perceptions during infectious disease outbreaks: a cross-sectional survey on COVID-19. J Med Internet Res. 2020;22(4):e18790 Pubmed PMID: 32240994; PubMed Central PMCID: PMC7124956.

39. Biasio LR, Bonacorsii G, Lorini C, Pecorelli S. Assessing COVID-19 vaccine literacy: a preliminary online survey. Hum Vacc Immunother. 2021;17(9):1304–12.

40. Buzuki K. Linguistic situation in twenty sub-Saharan African Countries: a survey-based approach. Afr Stud. 2016;75:358–80. https://doi.org/10.1080/002018416.201193376.

41. World Health Organization Regional Office for Africa [Internet]. Fifteen African countries hit 10% COVID-19 vaccination goal; c2021 [cited 2022 Jan 23]. Available from: https://www.afro.who.int/news/fifteen-african-countries-hit-10-covid-19-vaccination-goal.

42. Anjorin AA, Odetokun IA, Abioye AI, Elnadi H, Umoren MV, Damaris AA et al. Risk perception of COVID-19 among sub-Saharan Africans: a web-based comparative survey. Afr J Health. 2021;21(1):1562.

43. Africa Centers for Disease Control and Prevention [Internet]. COVID 19 vaccine perceptions: A 15 country study; c2021 [cited 2022 Jan 23]. Available from: https://africacdc.org/download/covid-19-vaccine-perceptions-15-country-study/.

44. Momplaisir FM, Kuter DJ, Chakraborty S, Loomis T, Bauch C, Okech B et al. Misinformation about COVID-19 in sub-Saharan Africa: evidence from a cross-sectional survey. Health Secure. 2021;19(1):44–56.

45. Robertson E, Reeve KS, Reeve KS, Moore J, Blake M, Green M et al. Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan. PLoS One. 2021;16(4):e0260575.

46. Lazarus JV, Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO et al. Hesitant or not? the association of age, gender, and education with potential acceptability of COVID-19 vaccine: a country-level analysis. J Health Commun. 2020;25(10):799–807. https://doi.org/10.1080/10810730.2020.1866830. (PubMed PMID: 33719881).

47. Osuagwu UL, Miner CA, Bhattachar D, Mashige KP, Oloruntoba R, Abu EK, et al. Misinformation about COVID-19 in sub-Saharan Africa: evidence from a cross-sectional survey. Health Secure. 2021;19(1):44–56.

48. King WC, Rubinstein M, Reinhart A, Mejia R, Cumbeer SN. Acceptability of COVID-19 Vaccine in Africa. Int J Mch Aids. 2021;10(1):134–8.

49. Costa JC, Weber AM, Darmstadt GL, Abdalla S, Victora CG. Religious affiliation and immunization coverage in 15 countries in Sub-Saharan Africa. Vaccine. 2020;38(5):1160–9.

50. Olagoke AA, Olagoke OQ, Hughes AM. Intention to vaccinate against the novel 2019 coronavirus disease: the role of health locus of control and religiosity. J Relig Health. 2021;60(1):65–80.

51. Chu J, Pink SL, Willer R. Religious identity cues increase vaccination intentions and trust in medical experts among American Christians. Proc Natl Acad Sci U S A. 2021;118(49):e2106481118.

52. Melillo S, Fountain D, Bormet M, O’Brien CJ. MOMENTUM Country and Global Leadership: Effects of faith actor engagement in the uptake and coverage of immunization in low- and middle-income countries (LMICs)* Phase I Global Landscape: Evidence Summary. c2021 [cited 2022 Jan 24]. Available from: https://usaidmomentum.org/wp-content/uploads/2021/07/Faith-Engagement-in-Immunization_Global-Landscape-AnalySis_Evidence-Summary-Report_June-2021-Sec508comp-low.pdf.

53. El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ. Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan. PLoS One. 2021;16(4):e0250555.

54. Wake AD. The willingness to receive COVID-19 vaccine and its associated factors: “vaccination refusal could prolong the war of this pandemic” - a systematic review. Risk Manag Healthc Policy. 2021,21(14):2609–23.

55. Algabban F, Algabban A. Vaccine hesitancy among healthcare providers during COVID-19 pandemic. Eur J Public Health. 2021;31 Suppl_7. doi: https://doi.org/10.1093/eurpub/ckb164.101.

56. Wirsy FS, Nkusi CN, Ako-Ameey DE, Dongeko EM, Manjeng FT, Cumbe‑ber SN. Acceptability of COVID-19 Vaccine in Africa. Int J Mch Aids. 2021;10(1):134–8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions